Fri, Aug 29, 2014, 8:48 AM EDT - U.S. Markets open in 42 mins.

Recent

% | $
Quotes you view appear here for quick access.

Nektar Therapeutics (NKTR) Message Board

  • gladpick gladpick Nov 23, 2012 10:47 AM Flag

    THIS IS AMAZING

    MAPP is up over 17% due to Levadex. NKTR is down 25 cents even though it has a Levadex partnership with MAP. What gives?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't get it either, imo nktr should be up on this news. but very low volume this day

    • According to NKTR IR, there are no milestone payments due for Levadex approval. Royalties are low to mid single digits. Levadex looks good on the resume, but it won't provide much money.

      • 2 Replies to dcxavier
      • "Now the AZN payments are at higher risk than they were before the SLXP CRL CC.. . . Where is the cash coming from in the next two years? . . . . Very few people ask these questions here. Benefits are obvious, risk has to be dug out."

        DCX, I think many of us identify risk but don't blow it out of proportion the way you do, crying like Cassandra that 118 cannot be salvaged unless another efficacy study is started immediately, and asking where oh where will the money ever come from?

        I for one pointed to the Adolor CV risk on this board over a year ago and suggested there was a real chance it would become an issue for the program. But that risk has not manifested yet, and I still think there is a very considerable chance (greater than 50-50 in my view), that if the safety data come back solid, the drug will be deemed safe and effective for its intended use by FDA. I also think it very, very likely that FDA will at a minimum accept the NDA filing, triggering a 90 million dollar payment to Nektar.

        If I am right about that latter point, Nektar will end 2013 with North of 200 million, even without deals on 181 or 102. And, notwithstanding your dismissive attitude toward the non-core assets, the fact is that the Affymax royalty stream will be a valuable asset -- just as the Cimzia/Mircera streams were -- if Affymax keeps going gangbusters for the next year. There are other non-core assets as well, such as the phase 3 inhaled Cipro program with Bayer.

        In short money is not what concerns me at the moment. If the data come back solid over the next 24-30 months on the 5 key programs or nearly all of them -- 118, 102, 181, Amikacin and Baxter -- then HR will figure out a way to extend the cash runway in nondilutive fashion, as he has done (with one exception) every time the Cassandras have cried that the Company is going to bust out over the last 5 years.

        As for your question on 102, let's take first things first. If we get accelerated approval, determining whether/when/how to finance a phase 3 study (or whether to partner the program at that point and get out of the way) won't be such a bad problem to have.

      • So lets say 5 million a Q ? 20m a year ? that's 3.3% of NKTR MC . that's why the stockprice doesn't reacts, its peanuts

 
NKTR
14.31+0.03(+0.21%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.